Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

215
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
215
Tumor Immunotherapy01:27

Tumor Immunotherapy

643
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
643
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

256
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
256
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Likelihood-based modeling of covariate-specific time-dependent receiver operating characteristic curves.

Statistical methods in medical research·2026
Same author

ALS untangled #83: clenbuterol.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

"What about me? I'm supposed to be … superhuman?": exploring staff perspectives on how to deliver high quality psychological care for people living with amyotrophic lateral sclerosis.

Neurodegenerative disease management·2026
Same author

ALSUntangled #82: N-acetylcysteine.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Patient and caregiver attitudes to cognitive and behavioral testing in Amyotrophic Lateral Sclerosis.

Neurodegenerative disease management·2026
Same author

Timing of communication and technology control support in ALS - a systematic review.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

An open-label Phase 2a study of fasudil in amyotrophic lateral sclerosis: safety and exploratory endpoints.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Noninvasive assessment of cardiovascular autonomic reflexes in amyotrophic lateral sclerosis: a systematic review.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

The connection between unproven stem cell-based interventions and complementary and alternative medicine in crowdfunding for Amyotrophic Lateral Sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Thinning of the oral motor cortex is linked to impaired speech in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Brain activity in an end-stage ALS patient suggests the presence of an unresponsive wakefulness syndrome.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Whole-body muscle MRI improves diagnostic certainty in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
See all related articles

Related Experiment Video

Updated: Aug 28, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

ALSUntangled #67: rituximab.

Xiaoyan Li1, Carmel Armon2, Paul Barkhaus3

  • 1Department of Neurology, Duke University, Durham, NC, USA.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|September 15, 2022
PubMed
Summary
This summary is machine-generated.

Rituximab, a B lymphocyte depleting drug, is not recommended for Amyotrophic Lateral Sclerosis (ALS) treatment. Current evidence does not support its use, and one patient reported no benefit, alongside serious risks.

Keywords:
ALSneuroinflammationoff-label treatmentrituximab

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K

Related Experiment Videos

Last Updated: Aug 28, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease.
  • Alternative and off-label treatments are frequently explored by patients.
  • Rituximab is a monoclonal antibody targeting B lymphocytes.

Purpose of the Study:

  • To evaluate the efficacy and safety of rituximab as an alternative treatment for ALS.
  • To review the current evidence regarding the role of B lymphocytes in ALS progression.

Main Methods:

  • Literature review of studies investigating rituximab for ALS.
  • Analysis of existing data on B lymphocyte involvement in ALS.
  • Case review of patients using rituximab for ALS.

Main Results:

  • No current evidence supports a role for B lymphocytes in ALS progression.
  • One reported case of rituximab use in ALS showed no patient benefit.
  • Rituximab carries known serious risks.

Conclusions:

  • The use of rituximab is not recommended for ALS treatment.
  • Further research is needed to understand potential therapeutic targets in ALS.
  • Patients should be aware of the risks associated with off-label drug use.